专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07094407B2 Fusion peptide containing human type-1 collagen derived peptide, preparation thereof, and skin anti-aging cosmetic composition comprising the same 有权
标题翻译：含有人1型胶原衍生肽的融合肽，其制备物和包含其的皮肤抗衰老化妆品组合物
公开(公告)号：US07094407B2
公开(公告)日：2006-08-22
申请号：US10243836
申请日：2002-09-16
申请人： Nae-Gyu Kang , Young-Sook Song , Sun-Gyoo Park , Yong-Hwa Lee , Wan-Goo Cho , Seh-Hoon Kang
发明人： Nae-Gyu Kang , Young-Sook Song , Sun-Gyoo Park , Yong-Hwa Lee , Wan-Goo Cho , Seh-Hoon Kang
IPC分类号： A61K39/00 , A61K38/04 , C12P21/06
CPC分类号： C07K14/005 , A61K8/65 , A61K2800/57 , A61Q19/08 , C07K14/78 , C07K2319/00 , C12N2740/16322 , Y10S514/844 , Y10S514/947
摘要： The present invention relates to a fusion peptide, in which a self cell-penetrating Tat peptide having a self penetrating signal is bound to a human Type-I collagen C-terminal derived peptide, a preparation thereof, and a skin anti-aging cosmetic composition comprising the same. Since the fusion peptide, in which the Tat peptide is bound to the human Type-collagen C-terminal derived peptide is highly stable and has a superior skin absorption capability, the present invention provides a skin anti-aging agent having superior synthesis of collagen and hyaluronic acid, anti-aging effects, and improved durability of the effects.
摘要翻译：本发明涉及一种融合肽，其中具有自身穿透信号的自细胞穿透Tat肽与人I型胶原C末端衍生肽结合，其制备物和皮肤抗衰老化妆品组合物包括它们。由于Tat肽与人类胶原C-末端衍生肽结合的融合肽是高度稳定的并且具有优异的皮肤吸收能力，因此本发明提供了具有优异的胶原合成的皮肤抗老化剂透明质酸，抗衰老作用，提高效果的耐久性。

2. 发明授权

US07060673B2 Fusion peptide of human parathyroid hormone derived peptide and tat peptide, preparation thereof, and skin slimming cosmetic composition comprising the same 有权
标题翻译：人甲状旁腺激素衍生的肽和tat肽的融合肽，其制备物和包含其的皮肤减肥化妆品组合物
公开(公告)号：US07060673B2
公开(公告)日：2006-06-13
申请号：US10296033
申请日：2002-05-06
申请人： Young-Sook Song , Nae-Gyu Kang , Sun-Gyoo Park , Wan-Goo Cho , Yong-Hwa Lee , Jun-Man Lim , Hye-Jung Min , Min-Youl Chang , Seh-Hoon Kang
发明人： Young-Sook Song , Nae-Gyu Kang , Sun-Gyoo Park , Wan-Goo Cho , Yong-Hwa Lee , Jun-Man Lim , Hye-Jung Min , Min-Youl Chang , Seh-Hoon Kang
IPC分类号： A61K38/00 , C12P21/04
CPC分类号： A61K8/64 , A61Q19/06 , C07K14/005 , C07K14/635 , C07K2319/00 , C12N2740/16322
摘要： The present invention relates to a fusion peptide wherein a self cell-penetrating Tat peptide having a self penetrating signal is bound to a human parathyroid hormone-derived peptide, a preparation thereof, and a skin slimming cosmetic composition comprising the same. Since the fusion peptide wherein the Tat peptide is bound to the human parathyroid hormone-derived peptide has high stability and superior skin absorption, the present invention provides a skin slimming agent having superior lipolysis effects and improved durability of the effects.
摘要翻译：本发明涉及一种融合肽，其中具有自身穿透信号的自身细胞穿透性Tat肽与人甲状旁腺激素衍生肽结合，其制备物和包含其的皮肤减肥化妆品组合物。由于Tat肽与人甲状旁腺激素衍生肽结合的融合肽具有高稳定性和优异的皮肤吸收性，因此本发明提供了具有优异的脂肪分解效果和改善的效果的耐久性的皮肤减肥剂。

3. 发明申请

US20050048629A1 Fusion peptide of human parathyroid hormone derived peptide and tat peptide, preparation thereof, and skin slimming cosmetic composition comprising the same 有权
标题翻译：人甲状旁腺激素衍生的肽和tat肽的融合肽，其制备物和包含其的皮肤减肥化妆品组合物
公开(公告)号：US20050048629A1
公开(公告)日：2005-03-03
申请号：US10296033
申请日：2002-05-06
申请人： Young-Sook Song , Nae-Gyu Kang , Sun-Gyoo Park , Wan-Goo Cho , Yong-Hwa Lee , Jun-Man Lim , Hye-Jung Min , Min-Youl Chang
发明人： Young-Sook Song , Nae-Gyu Kang , Sun-Gyoo Park , Wan-Goo Cho , Yong-Hwa Lee , Jun-Man Lim , Hye-Jung Min , Min-Youl Chang
IPC分类号： C12N15/09 , A61K8/00 , A61K8/64 , A61K8/72 , A61Q19/06 , C07K1/04 , C07K7/08 , C07K14/16 , C07K14/47 , C07K14/635 , C07K19/00 , C12P21/02 , C07H21/04 , C12P21/04
CPC分类号： A61K8/64 , A61Q19/06 , C07K14/005 , C07K14/635 , C07K2319/00 , C12N2740/16322
摘要： The present invention relates to a fusion peptide wherein a self cell-penetrating Tat peptide having a self penetrating signal is bound to a human parathyroid hormone-derived peptide, a preparation thereof, and a skin slimming cosmetic composition comprising the same. Since the fusion peptide wherein the Tat peptide is bound to the human parathyroid hormone-derived peptide has high stability and superior skin absorption, the present invention provides a skin slimming agent having superior lipolysis effects and improved durability of the effects.
摘要翻译：本发明涉及一种融合肽，其中具有自身穿透信号的自身细胞穿透性Tat肽与人甲状旁腺激素衍生肽结合，其制备物和包含其的皮肤减肥化妆品组合物。由于Tat肽与人甲状旁腺激素衍生肽结合的融合肽具有高稳定性和优异的皮肤吸收性，因此本发明提供了具有优异的脂肪分解效果和改善的效果的耐久性的皮肤减肥剂。

4. 发明授权

US07001744B2 Recombinant DNA, plasmid, transformed microorganism and vaccine protein for prevention and therapy of urinary tract infection 失效
标题翻译：重组DNA，质粒，转化微生物和疫苗蛋白，用于预防和治疗尿路感染
公开(公告)号：US07001744B2
公开(公告)日：2006-02-21
申请号：US10877670
申请日：2004-06-25
申请人： Suhk-Neung Pyo , Yong-Hwa Lee
发明人： Suhk-Neung Pyo , Yong-Hwa Lee
IPC分类号： C12P21/06
CPC分类号： A61K39/0258 , A61K39/107 , A61K2039/6037 , C07K14/245 , C07K14/28 , C12N15/62 , Y02A50/472 , Y02A50/474
摘要： Disclosed is a novel vaccine against Escherichia coli (E. coli) responsible for urinary tract infections. The vaccine is a recombinant chimeric protein which is prepared by linking by genetic recombination a gene encoding an antigenic determinant of uropathogenic E. coli to a CTXA2B gene encoding nontoxic A2 and B subunits of Vibrio cholerae cholera toxin (CTX) or a LTXA2B gene encoding nontoxic A2 and B subunits of E. coli heat-labile enterotoxin, wherein a translation product of the CTXA2B or LTXA2B gene serves as an immunogenic adjuvant stimulating mucosal immune responses, expressing the resulting recombinant gene in E. coli, and isolating and purifying an expressed recombinant fusion protein. The recombinant chimeric protein is useful as an oral vaccine with mild side effects and excellent vaccination efficiency against uropathogenic E. coli. Thus, the chimeric vaccine protein can remarkably reduce recurrence of urinary tract infections, prevent occurrence of antibiotic-resistant bacteria, and replace the conventional chemotherapy for urinary tract infections. Also, the chimeric vaccine protein has other advantages of being capable of being produced and commercialized in a short period with relatively low costs, and being easily modified by replacing its genetic constituents with other genes to provide various vaccines.
摘要翻译：公开了一种针对负责尿路感染的大肠杆菌（E. coli）的新型疫苗。该疫苗是通过基因重组将编码尿毒症大肠杆菌的抗原决定簇的基因与编码无毒性A2和抗弧菌霍乱弧菌毒素（CTX）的B亚基的CTXA2B基因或编码无毒的LTXA2B基因的基因重组相结合而制备的重组嵌合蛋白大肠杆菌热不稳定肠毒素的A2和B亚基，其中CTXA2B或LTXA2B基因的翻译产物用作刺激粘膜免疫应答的免疫原性佐剂，在大肠杆菌中表达所得重组基因，并分离和纯化表达的重组体融合蛋白。重组嵌合蛋白可用作具有轻度副作用的口服疫苗和针对致病性大肠杆菌的优良疫苗接种效率。因此，嵌合疫苗蛋白质可显着降低尿路感染的复发，预防抗生素耐药细菌的发生，并替代传统的化学治疗尿路感染。此外，嵌合疫苗蛋白质具有能够在相对较低成本的短时间内生产和商业化的其它优点，并且通过用其它基因替换其遗传成分以容易地修饰以提供各种疫苗。

5. 发明申请

US20050232938A1 Recombinant DNA, plasmid, transformed microorganism and vaccine protein for prevention and therapy of urinary tract infection 失效
标题翻译：重组DNA，质粒，转化微生物和疫苗蛋白，用于预防和治疗尿路感染
公开(公告)号：US20050232938A1
公开(公告)日：2005-10-20
申请号：US10877670
申请日：2004-06-25
申请人： Suhk-Neung Pyo , Yong-Hwa Lee
发明人： Suhk-Neung Pyo , Yong-Hwa Lee
IPC分类号： G06F17/30 , A61K39/02 , A61K39/106 , A61K39/108 , A61K39/116 , A61P13/02 , A61P31/04 , C07H21/04 , C07K14/245 , C07K14/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/31 , C12N15/62 , C12N15/63 , C12N15/70 , C12N15/74
CPC分类号： A61K39/0258 , A61K39/107 , A61K2039/6037 , C07K14/245 , C07K14/28 , C12N15/62 , Y02A50/472 , Y02A50/474
摘要： Disclosed is a novel vaccine against Escherichia coli (E. coli) responsible for urinary tract infections. The vaccine is a recombinant chimeric protein which is prepared by linking by genetic recombination a gene encoding an antigenic determinant of uropathogenic E. coli to a CTXA2B gene encoding nontoxic A2 and B subunits of Vibrio cholerae cholera toxin (CTX) or a LTXA2B gene encoding nontoxic A2 and B subunits of E. coli heat-labile enterotoxin, wherein a translation product of the CTXA2B or LTXA2B gene serves as an immunogenic adjuvant stimulating mucosal immune responses, expressing the resulting recombinant gene in E. coli, and isolating and purifying an expressed recombinant fusion protein. The recombinant chimeric protein is useful as an oral vaccine with mild side effects and excellent vaccination efficiency against uropathogenic E. coli. Thus, the chimeric vaccine protein can remarkably reduce recurrence of urinary tract infections, prevent occurrence of antibiotic-resistant bacteria, and replace the conventional chemotherapy for urinary tract infections. Also, the chimeric vaccine protein has other advantages of being capable of being produced and commercialized in a short period with relatively low costs, and being easily modified by replacing its genetic constituents with other genes to provide various vaccines.
摘要翻译：公开了一种针对负责尿路感染的大肠杆菌（E.coli）的新型疫苗。该疫苗是通过基因重组将编码尿毒症大肠杆菌的抗原决定簇的基因与编码无毒性A2和抗弧菌霍乱弧菌毒素（CTX）的B亚基的CTXA2B基因或编码无毒的LTXA2B基因的基因重组相结合而制备的重组嵌合蛋白大肠杆菌热不稳定肠毒素的A2和B亚基，其中CTXA2B或LTXA2B基因的翻译产物用作刺激粘膜免疫应答的免疫原性佐剂，在大肠杆菌中表达所得重组基因，并分离和纯化表达的重组体融合蛋白。重组嵌合蛋白可用作具有轻度副作用的口服疫苗和针对致病性大肠杆菌的优良疫苗接种效率。因此，嵌合疫苗蛋白质可显着降低尿路感染的复发，预防抗生素耐药细菌的发生，并替代传统的化学治疗尿路感染。此外，嵌合疫苗蛋白质具有能够在相对较低成本的短时间内生产和商业化的其它优点，并且通过用其它基因替换其遗传成分以容易地修饰以提供各种疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式